PURPOSE Baseline use of corticosteroids is associated with poor outcomes in patients with
non–small-cell lung cancer (NSCLC) treated with programmed cell death-1 axis inhibition …

Introduction We analysed patients with advanced non–small cell lung cancer (NSCLC) who
were treated with immune-checkpoint inhibitors (ICIs) to address the effect of the timeline …

Simple Summary Recently, the introduction of immunotherapy radically changed the
therapeutic algorithm of non-small-cell lung cancer as an upfront or secondary strategy …

Background Immune checkpoint inhibitors (ICIs) have shown significant improvements in
patients with advanced non–small cell lung cancer (NSCLC). One of the major issues with …

Purpose Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L) 1)
inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive …

Background Steroids are frequently used in patients with metastatic non-small cell lung
cancer (mNSCLC), but they could be detrimental for patients treated with immune …

Little is known regarding the effectiveness and tolerability of immune checkpoint inhibitor
(ICI) rechallenge after disease progression following initial ICI treatments. To identify eligible …

Background Studies have suggested that chemotherapy after immune checkpoint inhibitors
may confer an improved response for non–small cell lung cancer (NSCLC). However …

Background Limited data exist regarding the characteristics and survival outcomes of older
adults with non–small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors …

Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been
shown to improve survival in advanced non-small cell lung cancer (NSCLC). Unlike …